Amgen bugun AQSh oziq-ovqat va farmatsevtika idorasi (FDA) Amgen va AstraZeneca kompaniyasining Tezspire™ (tezepelumab-ekko) ni og'ir astma bilan og'rigan 12 yosh va undan katta yoshdagi kattalar va bolalar bemorlarini qo'shimcha parvarishlash uchun ma'qullaganini e'lon qildi.
eTurboNews maqolalar faqat obunachilar uchun. Obuna bu BEPUL.
Abonentlar bu yerga kirishadi BEPUL obuna bo'lish uchun shu yerni bosing
Abonentlar bu yerga kirishadi BEPUL obuna bo'lish uchun shu yerni bosing
USHBU MAQOLADAN NIMA OLISH KERAK:
- .
- Food and Drug Administration (FDA) has approved Amgen and AstraZeneca’s Tezspire™ (tezepelumab-ekko) for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
- eTurboNews maqolalar faqat obunachilar uchun.
